These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23275776)

  • 21. Emerging therapies for pancreas neuroendocrine cancers.
    Mahjoub AR; O'Reilly EM
    Chin Clin Oncol; 2013 Sep; 2(3):23. PubMed ID: 25841679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical treatment of gastroenteropancreatic neuroendocrine tumors.
    Rinke A; Michl P; Gress T
    Cancers (Basel); 2012 Feb; 4(1):113-29. PubMed ID: 24213230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis.
    Pozzari M; Maisonneuve P; Spada F; Berruti A; Amoroso V; Cella CA; Laffi A; Pellicori S; Bertani E; Fazio N
    Cancer Treat Rev; 2018 Dec; 71():39-46. PubMed ID: 30352319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacologic therapy for neuroendocrine tumours].
    Petrányi A; Bodoky G
    Orv Hetil; 2011 Mar; 152(10):379-91. PubMed ID: 21354954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management.
    Cloyd JM; Poultsides GA
    World J Gastroenterol; 2015 Aug; 21(32):9512-25. PubMed ID: 26327759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
    Peng L; Schwarz RE
    Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of ampullary neuroendocrine tumor by Capecitabine (Xeloda®) and Temozolomide (Temodal®).
    Noorali S; Haghighi S
    Gastroenterol Hepatol Bed Bench; 2021; 14(1):85-88. PubMed ID: 33868615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liver transplantation for unresectable pancreatic neuroendocrine tumors with liver metastases in an era of transplant oncology.
    Shimata K; Sugawara Y; Hibi T
    Gland Surg; 2018 Feb; 7(1):42-46. PubMed ID: 29629319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus.
    Viúdez A; Crespo G; Gómez Dorronsoro ML; Arozarena I; Marín-Méndez JJ; Custodio A; Benavent M; Goñi S; García-Paredes B; Hernando J; Durantez M; Alonso V; Riesco MDC; López C; Jiménez-Fonseca P; San Vicente BL; González-Borja I; Sevilla I; Hernández-Garcia I; Carmona-Bayonas A; Capdevila J; Pérez-Sanz J; García-Carbonero R; Pérez-Ricarte L; Llanos M; Vera R; De Jesús Acosta A
    Pancreatology; 2021 Jan; 21(1):215-223. PubMed ID: 33358592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of everolimus in adult patients with neuroendocrine tumors.
    Oberstein PE; Saif MW
    Clin Med Insights Oncol; 2012; 6():41-51. PubMed ID: 22253554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
    de Mestier L; Walter T; Brixi H; Evrard C; Legoux JL; de Boissieu P; Hentic O; Cros J; Hammel P; Tougeron D; Lombard-Bohas C; Rebours V; Ruszniewski P; Cadiot G
    Neuroendocrinology; 2019; 108(4):343-353. PubMed ID: 30759445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors.
    Cives M; Pelle' E; Quaresmini D; Mandriani B; Tucci M; Silvestris F
    Curr Treat Options Oncol; 2019 Jul; 20(9):72. PubMed ID: 31346813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
    Chan JA; Kulke MH
    Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Capecitabine plus temozolomide in well- or moderately-differentiated primary atypical neuroendocrine tumours - single-centre experience of two cases.
    La Salvia A; Brizzi MP; Muratori L; Trevisi E; Di Maio M; Scagliotti GV
    Endokrynol Pol; 2019; 70(4):380-383. PubMed ID: 30359462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs).
    Megdanova-Chipeva VG; Lamarca A; Backen A; McNamara MG; Barriuso J; Sergieva S; Gocheva L; Mansoor W; Manoharan P; Valle JW
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis.
    Rogowski W; Wachuła E; Gorzelak A; Lebiedzińska A; Sulżyc-Bielicka V; Iżycka-Świeszewska E; Żołnierek J; Kos-Kudła B
    Endokrynol Pol; 2019; 70(4):313-317. PubMed ID: 30843182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor.
    Sato A; Masui T; Sankoda N; Nakano K; Uchida Y; Anazawa T; Takaori K; Kawaguchi Y; Uemoto S
    Surg Case Rep; 2017 Dec; 3(1):82. PubMed ID: 28730577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sunitinib in pancreatic neuroendocrine tumors.
    Raymond E; Hammel P; Dreyer C; Maatescu C; Hentic O; Ruszniewski P; Faivre S
    Target Oncol; 2012 Jun; 7(2):117-25. PubMed ID: 22661319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.
    Gillen S; Schuster T; Meyer Zum Büschenfelde C; Friess H; Kleeff J
    PLoS Med; 2010 Apr; 7(4):e1000267. PubMed ID: 20422030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
    Pusceddu S; Vernieri C; Di Maio M; Marconcini R; Spada F; Massironi S; Ibrahim T; Brizzi MP; Campana D; Faggiano A; Giuffrida D; Rinzivillo M; Cingarlini S; Aroldi F; Antonuzzo L; Berardi R; Catena L; De Divitiis C; Ermacora P; Perfetti V; Fontana A; Razzore P; Carnaghi C; Davì MV; Cauchi C; Duro M; Ricci S; Fazio N; Cavalcoli F; Bongiovanni A; La Salvia A; Brighi N; Colao A; Puliafito I; Panzuto F; Ortolani S; Zaniboni A; Di Costanzo F; Torniai M; Bajetta E; Tafuto S; Garattini SK; Femia D; Prinzi N; Concas L; Lo Russo G; Milione M; Giacomelli L; Buzzoni R; Delle Fave G; Mazzaferro V; de Braud F
    Gastroenterology; 2018 Aug; 155(2):479-489.e7. PubMed ID: 29655834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.